Oh yeah, if you're taking UK approval for granted it really does seem like it would be terrible to stay in a company that just delivered the first real advancement in GBM treatment since the Stupp Protocol. It certainly doesn't make sense to stay while the UK parliament has been lamenting the current state of rare cancer care, mentioning brain tumors multiple times in session over the past month. Surely Keyoumars Ashkan's(congratulations on the MBE last month) advocacy for DCVAX wouldn't be of any help while Andrew Gwynne invites consultation for a new national cancer plan. Truly a terrible sequencing of events if one was looking to gain traction on restarting the broadly applicable Direct Program. Better get out 🙄
Market Data 
Markets 
AI
